WASHINGTON

华盛顿

,

，

June 10, 2026

2026年6月10日

/PRNewswire/ -- Danaher Corporation (NYSE:

/美通社/ -- 丹纳赫公司（纽约证券交易所：

DHR

DHR

), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.

），一家全球科技创新企业，今日宣布已完成对Masimo公司的收购。Masimo是一家领先的专科诊断提供商，主要提供脉搏血氧仪及其他患者监测解决方案，广泛应用于急症治疗场景。

Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market.

Masimo的信赖品牌、先进的传感器技术以及支持人工智能的患者监护功能，为丹纳赫诊断产品组合带来了互补且强大的新能力。通过此次交易，Masimo已成为丹纳赫的全资子公司，其普通股已停止在纳斯达克股票市场交易。

Masimo will continue to operate under the Masimo brand and will be a stand-alone operating company within Danaher's Diagnostics segment..

马西莫将继续以马西莫品牌运营，并成为丹纳赫诊断业务板块内一家独立运营的公司。

'Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo's growth and global reach,' said Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher. 'We are excited to welcome the Masimo team to Danaher.'.

“Masimo与丹纳赫具有高度的战略契合性。我们预计，双方将携手增强在急症护理领域提供差异化产品的能力，并加速Masimo的增长及其全球布局。”丹纳赫诊断业务执行副总裁朱莉·索耶·蒙哥马利表示，“我们很高兴欢迎Masimo团队加入丹纳赫。”

The consideration payable to former Masimo stockholders will be paid in accordance with the terms of the merger agreement, as further described in the definitive transaction materials filed with the U.S. Securities and Exchange Commission.

应付给前Masimo股东的对价将根据合并协议的条款支付，具体细节详见向美国证券交易委员会提交的最终交易文件。

Second Quarter and Full Year 2026 Outlook

2026年第二季度及全年展望

There is no change to Danaher's previously communicated second quarter and full-year 2026 guidance range, excluding the expected contribution from Masimo. The Company does not expect a material contribution from Masimo in the second quarter of 2026. The Company intends to update full-year 2026 guidance in connection with its second quarter earnings release to incorporate Masimo's expected contribution..

丹纳赫此前公布的2026年第二季度及全年业绩指引区间（不包括Masimo的预期贡献）维持不变。公司预计Masimo在2026年第二季度不会带来重大贡献。公司计划在发布第二季度财报时更新2026年全年指引，以纳入Masimo的预期贡献。

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

前瞻性陈述及其他信息

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the second quarter and full year 2026, expected strengthening of the Company's ability to deliver differentiated products in acute care settings, expected acceleration of Masimo's growth and global reach, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are 'forward-looking' statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S.

本新闻稿中非严格基于历史事实的陈述，包括关于公司2026年第二季度及全年预期财务业绩的陈述、关于公司在急症护理环境中提供差异化产品能力预期增强的陈述、关于Masimo增长和全球影响力预期加速的陈述，以及关于我们认为或预期将来会或可能发生的其他事件或发展的任何陈述，均属于联邦证券法意义上的“前瞻性”陈述。存在许多重要因素可能导致实际结果、发展和业务决策与此类前瞻性陈述所暗示或指出的情况存在重大差异，您不应过度依赖任何此类前瞻性陈述。这些因素包括但不限于：美国实施的关税及相关行动的影响。

and other countries, the impact of our debt obligations (including debt we have incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilit.

以及其他国家，我们的债务义务（包括为资助收购Masimo公司而产生的债务）对运营和流动性的影响，全球经济、我们所服务的市场以及金融市场的恶化或不稳定，人工智能在我们业务和产品中的开发、部署和使用方面的不确定性，全球健康危机的影响，与国家法律或政策相关的不确定性，包括旨在保护或促进国内利益和/或应对国外竞争的法律或政策，我们成功识别并完成适当收购和战略投资的能力，我们整合所收购业务并实现预期增长、协同效应及其他收益的能力，或有负债。

ABOUT DANAHER

关于丹纳赫

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

丹纳赫是全球领先的生命科学与诊断创新者，致力于加速发挥科学技术的力量以改善人类健康。通过我们由行业领先企业组成的互联生态系统，我们与客户携手合作，解决其众多最复杂的科学和临床挑战——帮助将创新成果更快地从发现阶段推向应用阶段，惠及依赖这些创新的患者。

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

依托丹纳赫业务系统，我们凭借先进的科学技术与经过验证的创新能力，助力实现更快、更精准的诊断，并缩短发现、开发和交付变革性疗法所需的时间，降低其成本与风险。通过持续改进和卓越运营，我们全球约6万名员工致力于产生持久影响，改善世界各地的生活质量，同时构建一个更健康、更可持续的明天。

Explore more at .

在 探索更多内容。

www.danaher.com

www.danaher.com

.

。

SOURCE Danaher Corporation

来源 丹纳赫公司

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示